Literature DB >> 31381897

Breaking Bad and Breaking Good: β-Cell Autophagy Pathways in Diabetes.

Kevin Vivot1, Adrien Pasquier2, Alexander Goginashvili3, Romeo Ricci4.   

Abstract

For many decades the lysosome has been recognized as the terminal center of cellular waste disposal. Products of lysosomal degradation are either recycled in biosynthetic pathways or are further metabolized to produce energy. As such the lysosome was attributed a rather passive role in cellular metabolism merely transforming bulk material into small metabolites. More recently, however, the emerging evidence has brought the lysosome to the center of nutrient sensing as the organelle that harbors a complex signaling machinery which dynamically and actively regulates cell metabolism. The pancreatic β cell is unique in as much as nutrient sensing is directly coupled to insulin secretion. Importantly, defects in insulin secretion constitute a hallmark in the progression of patients from a state of impaired glucose tolerance to full blown type 2 diabetes (T2D). However, mechanisms linking nutrient-dependent lysosomal function to insulin secretion and more generally to β cell health have evolved only very recently. This review discusses emerging concepts in macroautophagy and macroautophagy-independent processes of cargo delivery to lysosomes as well as nutrient-dependent lysosomal signaling specifically in the context of β cell function in health and disease. Such mechanisms may provide a novel source of therapeutic targets to be exploited in the context of β cell failure in diabetes in the near future.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Autophagy; Crinophagy; Diabetes; Lysosome; Nutrient signaling

Year:  2019        PMID: 31381897     DOI: 10.1016/j.jmb.2019.07.030

Source DB:  PubMed          Journal:  J Mol Biol        ISSN: 0022-2836            Impact factor:   5.469


  6 in total

Review 1.  Molecular prospect of type-2 diabetes: Nanotechnology based diagnostics and therapeutic intervention.

Authors:  Rout George Kerry; Gyana Prakash Mahapatra; Ganesh Kumar Maurya; Sushmita Patra; Subhasis Mahari; Gitishree Das; Jayanta Kumar Patra; Sabuj Sahoo
Journal:  Rev Endocr Metab Disord       Date:  2020-10-14       Impact factor: 6.514

Review 2.  Sugar-Lowering Drugs for Type 2 Diabetes Mellitus and Metabolic Syndrome-Review of Classical and New Compounds: Part-I.

Authors:  Raquel Vieira; Selma B Souto; Elena Sánchez-López; Ana López Machado; Patricia Severino; Sajan Jose; Antonello Santini; Ana Fortuna; Maria Luisa García; Amelia M Silva; Eliana B Souto
Journal:  Pharmaceuticals (Basel)       Date:  2019-10-10

3.  The nuclear receptor REV-ERBα is implicated in the alteration of β-cell autophagy and survival under diabetogenic conditions.

Authors:  Matthew R Brown; Damien Laouteouet; Morgane Delobel; Orianne Villard; Christophe Broca; Gyslaine Bertrand; Anne Wojtusciszyn; Stéphane Dalle; Magalie A Ravier; Aleksey V Matveyenko; Safia Costes
Journal:  Cell Death Dis       Date:  2022-04-15       Impact factor: 9.685

Review 4.  Endoplasmic Reticulum Stress and Dysregulated Autophagy in Human Pancreatic Beta Cells.

Authors:  Seoil Moon; Hye Seung Jung
Journal:  Diabetes Metab J       Date:  2022-07-27       Impact factor: 5.893

Review 5.  Beta-klotho in type 2 diabetes mellitus: From pathophysiology to therapeutic strategies.

Authors:  Shuang Hua; Qianying Liu; Jufei Li; Mengqi Fan; Kaixuan Yan; Dewei Ye
Journal:  Rev Endocr Metab Disord       Date:  2021-06-13       Impact factor: 6.514

Review 6.  Anti-Inflammatory and Pro-Autophagy Effects of the Cannabinoid Receptor CB2R: Possibility of Modulation in Type 1 Diabetes.

Authors:  Qing-Rong Liu; Kanikkai Raja Aseer; Qin Yao; Xiaoming Zhong; Paritosh Ghosh; Jennifer F O'Connell; Josephine M Egan
Journal:  Front Pharmacol       Date:  2022-01-18       Impact factor: 5.810

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.